IP Library Granted Patent US 12,403,086
Granted Patent B2
US 12,403,086 · App. 18/516,052 · Granted Sep 2, 2025

Solid drug tablets for implantable drug delivery devices

Inventors: Karen Danielle Daniel (Newton, MA); Burleigh M. Hutchins, III (Upton, MA); Cheryl Larrivee-Elkins (Framingham, MA); Heejin Lee (Bedford, MA)
Assignee: TARIS Biomedical LLC
A61K9/0004A61K9/0034A61K9/2027A61K9/2031A61K9/2072A61K9/2095A61K31/165A61K31/167A61M31/002A61M31/007B65B1/16A61K9/2004A61K31/16A61M2202/06
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,403,086
App. No.
18/516,052
Granted
Sep 2, 2025
Kind
B2
Abstract

A drug dosage form is provided in the form of a solid tablet which is greater than 50% by weight the local anesthetic agent. The local anesthetic agent may be selected from the group consisting of an aminoamide, an aminoester, and a combination thereof. The drug tablet may be in the form of a mini-tablet which is greater than 70 wt % drug, with the balance being excipient. For example, the anesthetic agent may include lidocaine, in a salt or base form, combined with binder and lubricant excipients. Implantable drug delivery devices including the tablets are also provided, e.g., one or more of the drug tablets may be contained in a biocompatible housing. The drug tablets may be substantially cylindrical with flat end faces, and the device may have from 10 to 100 drug tablets aligned in the housing with the flat end faces of adjacent tablets abutting one another.

Claims (35)

1. A method of manufacturing an assembly of tablets, comprising:

providing a plurality of tablets formed from a drug composition comprising a combination of a drug and one or more excipients, wherein the tablets are in the form of mini-tablets, wherein each mini-tablet is cylindrical with flat end faces, the length of the mini-tablet exceeding its diameter so that the mini-tablet has an aspect ratio of greater than 1:1;

arranging the plurality of tablets in a serial arrangement in which the flat end faces of adjacent tablets face one another; and

loading the serial arrangement into a drug delivery device which is configured for deployment within the body of a patient.

2. The method of claim 1 , wherein the providing the plurality of tablets comprises a process that includes granulating the drug and the one or more excipients to form the drug composition, and then tableting the drug composition.

3. The method of claim 2 , wherein the granulating comprises slugging, roller compaction, or fluid bed granulation.

4. The method of claim 1 , further comprising sterilizing the plurality of tablets after arranging the plurality of tablets in a serial arrangement.

5. An assembly of tablets, comprising:

a plurality of tablets in the form of mini-tablets containing a drug,

wherein each mini-tablet is cylindrical with flat end faces, the length of the mini-tablet exceeding its diameter so that the mini-tablet has an aspect ratio of greater than 1:1, and

wherein the plurality of tablets are configured in a serial arrangement in which the flat end faces of adjacent tablets face one another,

wherein the serial arrangement is disposed within a drug delivery device configured for deployment within the body of a patient.

6. The assembly of claim 5 , wherein the plurality of tablets comprises between 10 and 100 of the tablets.

7. The assembly of claim 5 , wherein the serial arrangement comprises interstices formed between adjacent ones of the tablets.

8. The assembly of claim 5 , wherein each mini-tablet has a diameter from 1.0 mm to 3.2 mm and a length from 1.7 mm to 4.8 mm, such that the mini-tablet is sized and shaped for insertion through the urethra of a patient and into the bladder.

9. The assembly of claim 8 , wherein each mini-tablet has a diameter from 1.5 mm to 3.1 mm and a length from 2.0 mm to 4.5 mm.

10. The assembly of claim 5 , wherein each mini-tablet contains greater than 70% by weight the drug.

11. The assembly of claim 5 , wherein each mini-tablet comprises the drug in an amount between 70 wt % and 99 wt % of the mini-tablet.

12. The assembly of claim 5 , wherein the drug is an anesthetic agent, an antimicrobial agent, or a chemotherapeutic agent.

13. The assembly of claim 5 , wherein the mini-tablets further comprise excipients comprising a binder and a lubricant.

14. The assembly of claim 5 , wherein each mini-tablet has a friability of less than 2%.

15. The assembly of claim 5 , wherein each mini-tablet is sterilized.

16. The assembly of claim 5 , wherein each mini-tablet has an aspect ratio from about 3:2 to about 5:2.

17. An assembly of drug tablets, comprising:

a plurality of drug of tablets containing a drug, the plurality being from 10 to 100 drug tablets,

wherein each tablet is cylindrical with flat end faces, the length of the tablet exceeding its diameter so that the tablet has an aspect ratio from 3:2 to 5:2,

wherein the plurality of drug tablets are configured in a serial arrangement in which the flat end faces of adjacent tablets face one another, and

wherein each tablet has a friability of less than 2%,

wherein the serial arrangement is disposed within a drug delivery device configured for deployment within the body of a patient.

18. The assembly of claim 17 , wherein the serial arrangement comprises interstices formed between adjacent ones of the tablets and the assembly is sized and shaped for insertion through the urethra of the patient and into the bladder of the patient.

19. The assembly of claim 18 , wherein each tablet has a diameter from 1.5 mm to 3.1 mm and a length from 2.0 mm to 4.5 mm and comprises the drug in an amount between 70 wt % and 99 wt % of the tablet.

20. The assembly of claim 19 , wherein the drug is a chemotherapeutic agent and the tablets comprise excipients comprising a binder and a lubricant.

21. The method of claim 1 , wherein the drug comprises gemcitabine.

22. The assembly of claim 5 , wherein the drug comprises gemcitabine.

23. The assembly of claim 17 , wherein the drug comprises gemcitabine.

Assignments (4)
MERGER Recorded May 6, 2026
From: TARIS BIOMEDICAL LLC
To: JANSSEN BIOTECH, INC.
Reel/Frame 074576/0807 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 12, 2024
From: DANIEL, KAREN DANIELLE; HUTCHINS, BURLEIGH M., III; LARRIVEE-ELKINS, CHERYL; LEE, HEEJIN
To: TARIS BIOMEDICAL LLC
Reel/Frame 069565/0389 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 12, 2024
From: LIRIS BIOMEDICAL, INC.
To: TARIS BIOMEDICAL LLC
Reel/Frame 069566/0001 →
CHANGE OF NAME Recorded Dec 12, 2024
From: TARIS BIOMEDICAL LLC
To: LIRIS BIOMEDICAL, INC.
Reel/Frame 069613/0176 →
Continuity (8)
Continuation 17352740 · Jun 21, 2021
Continuation 16932229 · Jul 17, 2020
Continuation 15633492 · Jun 26, 2017
Continuation 13729974 · Dec 28, 2012
Continuation 12825238 · Jun 28, 2010
Provisional Application 61241382 · Sep 10, 2009
Provisional Application 61220865 · Jun 26, 2009
Related Publication 20240091136A1 · Mar 21, 2024
References Cited (51)
US 4016251A · Higuchi et al. · 1977 [cited by applicant]
US 4210670A · Cooke · 1980 [cited by applicant]
US 4475916A · Himmelstein · 1984 [cited by applicant]
US 4578075A · Urquhart et al. · 1986 [cited by applicant]
US 4797287A · Pich · 1989 [cited by applicant]
US 4871542A · Vilhardt · 1989 [cited by applicant]
US 5023088A · Wong et al. · 1991 [cited by applicant]
US 6039967A · Ottoboni et al. · 2000 [cited by applicant]
US 6086909A · Harrison et al. · 2000 [cited by applicant]
US 6159143A · Lennox · 2000 [cited by applicant]
US 6171298B1 · Matsuura et al. · 2001 [cited by applicant]
US 6524608B2 · Ottoboni et al. · 2003 [cited by applicant]
US 8521273B2 · Kliman · 2013 [cited by applicant]
US 20030017198A1 · Yeh et al. · 2003 [cited by applicant]
US 20030143268A1 · Pryce · 2003 [cited by applicant]
US 20040260272A1 · Friedman et al. · 2004 [cited by applicant]
US 20050142075A1 · Rast · 2005 [cited by applicant]
US 20050192210A1 · Rothbard · 2005 [cited by applicant]
US 20050234013A1 · Parsons · 2005 [cited by applicant]
US 20050238733A1 · Henry · 2005 [cited by applicant]
US 20060105010A1 · Rahe et al. · 2006 [cited by applicant]
US 20060264912A1 · Mcintyre et al. · 2006 [cited by applicant]
US 20070172508A1 · Zupkas et al. · 2007 [cited by applicant]
US 20080044450A1 · Brandon et al. · 2008 [cited by applicant]
US 20080111269A1 · Politi et al. · 2008 [cited by applicant]
US 20090149833A1 · Cima et al. · 2009 [cited by applicant]
US 20090317465A1 · Peppas · 2009 [cited by applicant]
US 20100003297A1 · Tobias et al. · 2010 [cited by applicant]
US 20100331770A1 · Lee et al. · 2010 [cited by applicant]
US 20110060309A1 · Lee et al. · 2011 [cited by applicant]
US 20130084333A1 · Dick et al. · 2013 [cited by applicant]
JP 10298107A · 1998 [cited by applicant]
WO 9509169A1 · 1995 [cited by applicant]
WO 9725990A1 · 1997 [cited by applicant]
WO 9744021A1 · 1997 [cited by applicant]
WO 9918884A1 · 1999 [cited by applicant]
WO 0180822A3 · 2001 [cited by applicant]
WO 02000203A1 · 2002 [cited by applicant]
WO 02005800A2 · 2002 [cited by applicant]
WO 2005044702A1 · 2005 [cited by applicant]
WO 07021964A2 · 2007 [cited by applicant]
WO 2007012439A1 · 2007 [cited by applicant]
WO 08051889A1 · 2008 [cited by applicant]
WO 09029958A1 · 2009 [cited by applicant]
Giannantoni, et al., “New Frontiers in Intravesical Therapies and Drug Delivery,” European Urology, vol. 50 (2006), pp. 1183-1193, Elsevier B.V. [cited by applicant]
Rosa et al., Anesth. Prog. 46:97-99, 1999. [cited by applicant]
Tyagi, et al., “Local Drug Delivery to Bladder Using Technology Innovations,” Urological Clinics of North America, vol. 33 (2006), pp. 519-530, Elsevier Inc. [cited by applicant]
Hug CC Jr., J. Pain Symptom Manage. Aug. 1992; 7(6):350-5. [cited by applicant]
Huynh-Ba, “Handbook of Stability Testing in Pharmaceutical Development”, (2009), p. 215. [cited by applicant]
Henry, et al., “Topical Anesthesia of the Bladder,” Abstracts, A61. [cited by applicant]
Rhines, T., “Non-chromatographic Methods to Support Stability Program,” Handbook of Stability Testing in Pharmaceutical Development, 2009, p. 215, Springer Science + Business Media, LLC. [cited by applicant]